P1, N=309, Active, not recruiting, Immune-Onc Therapeutics | Phase classification: P1b --> P1 | Trial completion date: Dec 2024 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Mar 2024

2 months ago

Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases

Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • IO-108

7ms

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1b, N=309, Active, not recruiting, Immune-Onc Therapeutics | Recruiting --> Active, not recruiting

7 months ago

Enrollment closed • Combination therapy • Metastases

Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • IO-108

12ms

Novel Myeloid Checkpoint Inhibitors Targeting the LILRB (ILT) Family Members (PEGS 2023)

These include IO-108, an antagonist antibody targeting LILRB2 (ILT4), in Phase I clinical development for solid tumors and IO-202; an antagonist antibody targeting LILRB4 (ILT3), in Phase I clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1; IO-312, a novel bispecific antibody targeting LILRB4 and CD3 (LILRB4 x CD3); and multiple undisclosed programs.

12 months ago

Checkpoint inhibition

LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)

IO-202 • IO-106 • IO-108 • IO-312

2years

IO-108, A fully human therapeutic antibody blocking the myeloid checkpoint LILRB2/ILT4, promotes innate and adaptive anti-cancer immunity in preclinical studies (AACR 2022)

Importantly, IO-108 presents a favorable pharmacokinetic and safety profile in preclinical models. Collectively, the preclinical characterization of IO-108 enabled a comprehensive clinical biomarker plan and lends rationale to the clinical study (NCT05054348) of IO-108 as a novel immunotherapy for multiple solid tumor types, including those relapsed/refractory to standard of care therapies.

2 years ago

Preclinical • PD(L)-1 Biomarker • IO biomarker

CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1)

IO-108